Navigation Links
Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
Date:11/10/2011

tiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or CHMP's 120-day questions, the FDA's requests stemming from the end-of-review meeting or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP's safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  VIVUS does not undertake an obligation to update or revise any forward-looking statements.  Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:   VIVUS, Inc.Investor Relations:  The Trout GroupTimothy E. MorrisBrian Korb Chief Financial Officerbkorb@troutgroup.com 650-934-5200646-378-2923
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
2. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
3. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
4. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
5. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
6. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
7. LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
8. Discovery Labs Releases New AFECTAIR™ Performance Data Presented at the American Association for Respiratory Care Annual Meeting
9. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
10. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
11. Bayer HealthCares MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  ANI Pharmaceuticals, Inc. ... Company plans to release its second quarter and year-to-date ... the opening of the U.S. financial markets. The earnings ... section of the Company,s website, www.anipharmaceuticals.com . ... Executive Officer, and Charlotte C. Arnold , Vice ...
(Date:7/28/2014)... , July 28, 2014 PDL BioPharma, Inc. (PDL) ... will release its second quarter 2014 financial results for the ... after market close. PDL,s management will host a conference call ... discuss the financial results.  A slide presentation relating to the ... PDL website. Conference Call Details To access ...
(Date:7/28/2014)...  ProteinSimple announced today that it has launched a ... allows users to detect all proteins separated in the ... can analyze proteins without the need for an antibody.  ... analysis as we know it today. First, the Simple Western ... messy gels, no transfer tanks, no blots, no imaging ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2
(Date:7/28/2014)... University School of Medicine (BUSM) report variants in a ... developing Alzheimer,s disease (AD). The discovery of this novel ... that target PLXNA4 specifically. These findings appear in the ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people age 85 and ...
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and ... forecast of revenue. The Wireline services market in Europe is ... $2.4 billion by 2019, at a CAGR of 11.2%, for ... Wireline Services Market in Europe report, to get an idea ... of the segmentation in the European Wireline Services market, and ...
(Date:7/28/2014)... 28, 2014 (HealthDay News) -- A common inflammatory ... older people may increase the risk for heart ... A British study found that patients with polymyalgia ... -- conditions that affect the blood vessels. Doctors ... patients with polymyalgia rheumatica to reduce their risk ...
(Date:7/28/2014)... July 28, 2014A two-step decision tree analysis, incorporating ... and distill the many available quality standards, guidelines, ... national and international quality standards for radiation therapy, ... 2014 issue of Practical Radiation Oncology ... American Society for Radiation Oncology (ASTRO). , Guidelines, ...
(Date:7/28/2014)... Mediaplanet announced distribution of its third ... campaign that aims to raise awareness about the benefits ... TEALUX , a premium loose leaf tea shop ... readers with educational insight about the accessibility and growth ... forward and make conscious organic choices an option for ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... Systems on the Role of Information Technology in Improving HealthcarePLANO, Texas, April 30 ... executive vice president and chief, ... Dr. Nathaniel Hupert, Director of The Preparedness Modeling Unit, ... Control and Prevention (CDC) and, ...
... their homes is the focus of Penn State,s portion ... that will also test the efficacy of a workplace ... "We,re seeing that stress in the workplace can create ... quality of life in families," says David Almeida, professor ...
... Practice LeaderNEW YORK, April 30 RSM McGladrey, ... a major expansion in the visibility of the ... York office. The expansion will be led by ... in the EBP sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20080305/AQW023LOGO )"Companies ...
... Leaders and National Organizations Respond to Increasing Support ... DebateWASHINGTON, April 30 Men,s Health Network applauds ... today for introducing H.R. 2115, the "Men and ... would establish an Office of Men,s Health within ...
... the Newest Innovation in the Anthelios Franchise for UVA ... April 30 La Roche-Posay, the company that brought ... proudly announces the availability of Anthelios 60 Sunscreen(1) beginning ... brand,s new revolutionary sunscreen range offers ...
... WA April 30, 2009 Biogen Idec (NASDAQ: ... High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study ... to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention ... granted approval for use in patients who experienced their ...
Cached Medicine News:Health News:Looking Forward: The Use of Health IT in Crisis 2Health News:Looking Forward: The Use of Health IT in Crisis 3Health News:Looking Forward: The Use of Health IT in Crisis 4Health News:Penn State plays integral role in $35 million stress project 2Health News:RSM McGladrey and McGladrey & Pullen LLP Announce Major Expansion of Employee Benefits Plan Practice in New York 2Health News:RSM McGladrey and McGladrey & Pullen LLP Announce Major Expansion of Employee Benefits Plan Practice in New York 3Health News:U.S. Representatives Hill and Murphy Introduce the 'Men and Families Health Care Act of 2009' 2Health News:Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide 2Health News:Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide 3Health News:First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients 2
Triad Plus PVP-I Scrub Winged Sponges...
Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
Medicine Products: